New vaccine technology tested to better protect vulnerable transplant patients from COVID-19
NCT ID NCT07390968
Summary
This study is testing a new type of COVID-19 vaccine designed to work better in people who have received a blood or marrow transplant. It compares this experimental vaccine, called LUNAR-COV19, to the approved Pfizer Comirnaty vaccine. The goal is to see if the new vaccine is safe and can create a stronger, longer-lasting immune response in these patients, whose immune systems are often weakened by their transplant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC AND LYMPHATIC SYSTEM NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.